Barclays
KRYS icon

Barclays’s Krystal Biotech KRYS Stock Holding History

Barclays’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,000
Closed -$3.56M – 5108
2024
Q1 		$3.56M Buy
+20,000
New +$2.78M ﹤0.01% 2082

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's KRYS Position: Q1 2026 in Review

Barclays reduced its Krystal Biotech (KRYS) stake by 92% in Q1 2026, selling an estimated $14.7M and leaving 4,969 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2596.

Barclays first reported a position in KRYS in Q4 2018 and has held it in 30 quarters since. The position peaked at $14.8M in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Barclays held 4,969 shares of Krystal Biotech worth $1.28M as of Q1 2026.
  • Barclays sold 55,093 Krystal Biotech shares in Q1 2026, an estimated $14.7M.
  • Krystal Biotech made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2596 holding.
  • Barclays first reported a position in Krystal Biotech in Q4 2018 and has held it in 30 quarters since.
  • Barclays's Krystal Biotech position peaked at $14.8M in Q4 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.